Disease Progression and Hospitalization

Add UPTRAVI Earlier in FC II and FC III Before Progression Takes More Away

PRIMARY ENDPOINT: TIME TO FIRST PAH DISEASE PROGRESSION EVENT IN GRIPHON1

Time to first disease progression event
The treatment effect was established early and maintained over the entire treatment period

UPTRAVI is the ONLY Oral Prostacyclin Pathway Therapy Proven to Reduce the Risk of Hospitalization for PAH1

GRIPHON trial: Hospitalization for PAH as the first event

Hospitalization as first event up to end of treatment: